Furthermore, Lekas et al. [22] reported in a prospective, randomized study that finasteride administration for 25.3 weeks on average to BPH patients resulted in the suppression of MVD as well as vascular endothelial growth factor and hypoxia-inducible factor-1α expression in a time-dependent manner, where MVD was assessed by counting CD34-positive microvessels in the three most vascularized high-power fields. Here, CD34 is linked to benign prostatic hyperplasia.